3-(dimethylamino)-1-(3-fluorophenyl)prop-2-en-1-one | 96604-93-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(dimethylamino)-1-(3-fluorophenyl)prop-2-en-1-one
• 英文别名: 3-(Dimethylamino)-1-(3-fluorophenyl)-2-propen-1-one
• CAS: 96604-93-2
• 化学式: C₁₁H₁₂FNO
• 分子量: 193.221
• InChiKey: MJEQZIDZSNCFKG-UHFFFAOYSA-N

物化性质

• 沸点：
  270.8±40.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(dimethylamino)-1-(3-fluorophenyl)prop-2-en-1-one 在 吡啶 、 sodium hydroxide 作用下， 以 异丙醇 为溶剂， 反应 5.0h， 生成 N-(4-(3-fluorophenyl)pyrimidin-2-yl)-2-methyl-5-nitrobenzamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors

  摘要：

  36 new compounds with the typical skeleton of 4-anilino-5-vinyl/ethynyl pyrimidine, 4-anilino-3-cyano-5-vinyl/ethynyl/phenyl pyridine, and m-amino-N-phenylbenzamide, are designed, synthesized and selectively tested on EGFR, ErbB-2 kinases, and A-549, HL60 cells growth inhibition. Results from the bioactivity and chemical structures yield preliminary structure-activity relationships (SARs). The most potent 5-ethynylpyrimidine derivative 20a has an IC50 value of 45 nM to EGFR kinase. Several compounds of other series also show IC50 values <1 mu M for EGFR and <5 mu M for A-549 and HL60 cells growth inhibition. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2013.03.053
• 作为产物：
  描述：

  N,N-二甲基甲酰胺二甲基缩醛 、 3'-氟苯乙酮 以 甲苯 为溶剂， 生成 3-(dimethylamino)-1-(3-fluorophenyl)prop-2-en-1-one
  参考文献：
  名称：

  I2-促进 [4 + 2] 原位生成的偶氮烯烃与烯胺酮的环加成：1,4-二氢哒嗪和哒嗪的简便有效合成

  摘要：

  已经开发了一种通过 I 2 -促进的 [4 + 2]原位生成的偶氮烯烃与烯胺酮环加成来合成 1,4-二氢哒嗪和哒嗪的简便有效的策略。选择性的转换归因于对不同反应温度的明智选择。这项工作的主要特点包括可控和选择性合成、良好的官能团耐受性、良好的反应收率、无金属/碱基条件以及一锅法的适用性。

  DOI：

  10.1039/d0ob01958e

文献信息

• 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080214520A1

  公开（公告）日：2008-09-04

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R 6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

  本发明提供了Formula I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：Formula (I)其中：R6选自(a、b、c、d、e)等基团组成的群，其他取代基如规范中定义。
• I₂-Promoted [4 + 2] cycloaddition of <i>in situ</i> generated azoalkenes with enaminones: facile and efficient synthesis of 1,4-dihydropyridazines and pyridazines
  作者：Jiajun Feng、Tiantong He、Yuxing Xie、Yang Yu、Jonathan B. Baell、Fei Huang

  DOI：10.1039/d0ob01958e

  日期：——

  A facile and efficient strategy for the synthesis of 1,4-dihydropyridazines and pyridazines through I2-promoted [4 + 2] cycloaddition of in situ generated azoalkenes with enaminones has been developed. The switch in selectivity is attributed to the judicious choice of different reaction temperatures. The key features of this work include controllable and selective synthesis, good functional group tolerance

  已经开发了一种通过 I 2 -促进的 [4 + 2]原位生成的偶氮烯烃与烯胺酮环加成来合成 1,4-二氢哒嗪和哒嗪的简便有效的策略。选择性的转换归因于对不同反应温度的明智选择。这项工作的主要特点包括可控和选择性合成、良好的官能团耐受性、良好的反应收率、无金属/碱基条件以及一锅法的适用性。
• Method of using substituted pyrazolo [1,5-a] pyrimidines
  申请人：Wang Daniel Yanong

  公开号：US20060063784A1

  公开（公告）日：2006-03-23

  This invention relates to novel methods of use of certain pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. This invention also relates to novel methods of using these compounds as anti-proliferative agents in mammals, including humans.

  这项发明涉及某些吡唑并[1,5-a]嘧啶化合物及其治疗上可接受的盐的新用途方法。该发明还涉及将这些化合物作为抗增殖剂在哺乳动物，包括人类中的新用途方法。
• An efficient method for the synthesis of 2-pyridones <i>via</i> C–H bond functionalization
  作者：Shuguang Zhou、Duan-Yang Liu、Suo Wang、Jie-Sheng Tian、Teck-Peng Loh

  DOI：10.1039/d0cc06834a

  日期：——

  A simple and practical method to access N-substituted 2-pyridones via a formal [3+3] annulation of enaminones with acrylates based on RhIII-catalyzed C–H functionalization was developed. Control and deuterated experiments led to a plausible mechanism involving C–H bond cross-coupling and aminolysis cyclization. This strategy provides a short synthesis of structural motifs of N-substituted 2-pyridones

  开发了一种简单实用的方法，通过基于Rh III催化的C–H官能化，通过烯丙酮与丙烯酸酯的正式[3 + 3]环合反应，获得N-取代的2-吡啶酮。对照和氘代实验导致了一个合理的机制，涉及C–H键交叉偶联和氨解环化。该策略提供了N-取代的2-吡啶酮的结构基序的简短合成。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014089364A1

  公开（公告）日：2014-06-12

  Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本文提供了替代嘧啶基吡唑啉、嘧啶基吡唑啉和嘧啶基吡咪啉衍生物化合物以及包含这些化合物的药物组合物。这些化合物和组合物对于抑制组蛋白去甲基化酶具有用途。此外，这些化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等癌症有用。